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 Abstract | Much time, effort and investment goes into the diagnosis of symptomatic cancer, with 
the expectation that this approach brings clinical benefits. This investment of resources has been 
particularly noticeable in the UK, which has, for several years, appeared near the bottom of 
international league tables for cancer survival in economically developed countries. This Review 
examines expedited diagnosis of cancer from four perspectives. The first examines the potential for 
benefits from expedited diagnosis of symptomatic cancer. Limited evidence from clinical trials is 
available, but the considerable observational evidence suggests benefits can be obtained from this 
approach. The second perspective considers how expedited diagnosis can be achieved. We 
concentrate on data from the UK, where extensive awareness campaigns have been conducted, and 
initiatives in primary care, including clinical decision support, have all occurred during a period of 
considerable national policy change. The third section considers the most appropriate patients for 
cancer investigations, and the possible community settings for this. UK national guidance for 
selection of patients for investigation is discussed. Finally, the health economics of the subject are 
reviewed, although few studies provide definitive evidence on this topic.  
 
 
 
 
 
In all developed countries, much time, effort and finance is spent on the diagnosis of cancer.1 This 
expenditure is based on the assumption that diagnosis of cancer and, in particular, early diagnosis of 
cancer, is beneficial. Cancer can be diagnosed before it generates symptoms. Early diagnosis is 
generally achieved using formal screening, or surveillance of those deemed to be at a high risk of 
developing cancer ?ƐƵĐŚĂƐƉĂƚŝĞŶƚƐǁŝƚŚůŽŶŐƐƚĂŶĚŝŶŐŝŶĨůĂŵŵĂƚŽƌǇďŽǁĞůĚŝƐĞĂƐĞŽƌĂƌƌĞƚƚ ?Ɛ
oesophagus; although, some cancers are identified serendipitously when a suspicion of cancer is not 
the primary reason for the clinical examination. Screening and surveillance are not considered 
further in this Review, other than to remark that the successful promotion of screening programmes 
has strengthened public perception that the earlier that a cancer is diagnosed, the better the 
outcomes will be. 
Before reviewing the evidence regarding how the diagnosis of symptomatic cancer can be improved, 
briefly reviewing why diagnosis of symptomatic cancer is necessary and should be improved is 
important. Only by being explicit about what we are hoping to achieve can we design services to 
meet our needs optimally. Thus, this review has four parts: the benefits of expedited symptomatic 
diagnosis (the  ‘why ?); achieving expedited diagnosis of cancer (the  ‘how ?); patient and population 
aspects of cancer diagnosis (the  ‘who and where ?); and the health economics of expedited cancer 
diagnosis (the  ‘how much ?). This review focusses largely on early diagnosis of symptomatic cancer in 
the UK, although, published data from studies conducted in other countries is referred to where 
relevant  
 
[H1] Benefits of expedited symptomatic diagnosis  
[H2] Types of evidence 
The case for expedited diagnosis of cancer is built upon many individual pieces of largely 
observational evidence, with several potential biases (BOX 1). Few randomized trials have been 
conducted in this area, mainly because offering potential participants the possibility of an arm that 
appears to delay the diagnosis of cancer is difficult. The perception that rapid diagnosis of cancer is 
essential means that patients are unlikely to participate, making ethical approval difficult or 
impossible. However, trials comparing different diagnostic modalities can be performed. To date, 
these have mainly been conducted in the setting of secondary care: one example is provided by the 
SIGGAR trial, which was designed to compare the effectiveness of CT colonography versus that of 
colonoscopy in individuals with symptoms suggestive of colorectal cancer.2 An alternative approach 
is to perform trials of cancer diagnostics in a community care setting, and a number of trials using 
this approach now have results available, or are in progress. These cover a variety of interventions: 
promoting earlier presentation of potential cancer symptoms3-7; the use of new technologies in the 
assessment of pigmented skin lesions8; the use of computerized decision-support tools in the 
diagnosis of cancer in primary care 9; cancer-specific education for general practitioners (GPs)5, 10; 
direct access to low-dose CT for the early detection of lung cancer in primary care11; and lower 
symptom thresholds for urgent use of chest radiography12. Thus far, no trial has included a 
sufficiently large cohort to address the issue of whether or not expedited cancer diagnosis in primary 
care is beneficial, in terms of either mortality or morbidity.  
[H2] Survival and diagnostic activity 
Cancer survival provides the main rationale for expedited cancer diagnosis. This rationale is 
enshrined in numerous governmental publications internationally 13, 14 Among developed countries, 
the UK and Denmark have regularly appeared at the bottom of tables ranking the survival of patients 
with cancer.15-18 These poor outcomes, relative to those of similar patients in other developed 
countries, are considered to arise in a large part from differences in the availability of, and 
willingness to use cancer diagnostic investigations, perhaps augmented by a decreased willingness of 
patients in England to seek medical care compared with those in Europe.19 Investigators in one study 
reported an inverse relationship between cancer survival rates and the degree of separation of 
primary care from specialist care in health-care systems (the so-ĐĂůůĞĚ ‘ŐĂƚĞŬĞĞƉĞƌƌŽůĞ ?ŽĨprimary 
care, whereby access to specialist care requires a referral from primary care).20 Gatekeeping is a 
common feature of health-care systems that deliver better overall population outcomes;21 although, 
this counterintuitive finding of an association with poor cancer survival might be explained by the 
relative  unwillingness of GPs to test for cancer when the risk of a hitherto undiagnosed cancer is 
small. This perception is supported by an international vignette study, across primary care physicians 
practicing in one of 12 different geographical areas, in which investigators asked GPs about their 
management of fictitious patients with clinical scenarios representing a small risk of cancer. This 
revealed a highly significant relationship between the willingness of the GP to investigate the 
possible cancer and higher national survival rates of patients with that cancer (P <0.05 for four of the 
five scenarios).22 This relationship is also seen at a general practice level. In a study of upper 
gastrointestinal endoscopy rates in England, patients undergoing clinical examinations in general 
practices ranked in the highest third for endoscopy rates (mean of 12.9 procedures per 1,000 adults 
per year) had superior gastro-oesophageal cancer outcomes, including better overall survival (OR 1 
versus 1.14, 95% CI 1.06 W1.22; P <0.001) and fewer emergency admissions (OR 1 versus 1.53, 95% CI 
1.42 W1.65; P <0.001) than those undergoing examinations at practices in the lower third for 
endoscopy rates (mean of 4.4 procedures per 1000 adults per year) 23 Conversely, results of a study 
using electronic records of primary care data to investigate outcomes of patients with lung cancer 
revealed an association between higher general practice chest radiography rates and increased odds 
of early death from lung cancer when comparing the highest  ?A? ? ? ? ?chest examination per 100 of 
population) and lowest (1 W2.73 examination per 100 of population) quartiles for chest radiography 
(OR 0.85; 95% CI 0.75 W0.97).24 Despite this positive finding, authors of this study did not report 
survival figures, and the increased mortality might well reflect the presence of ascertainment bias 
(see BOX 1). However, a 2012 report from Leeds, following extensive campaigning to increase chest 
radiography rates, has shown a reduction in the percentage of patients with lung cancer presenting 
as an emergency from 33% in 2008 W2010 to 28% in 2011 (P = 0.035), with a small improvement in 
180-day mortality.25 
Considerable variation exists in the use of cancer testing in the UK; for example, in 2012 W2013 a 3.6-
fold difference in CT use was observed between primary care trusts with the highest and lowest CT 
use, and a 3.1-fold difference in use of non-obstetric ultrasonography among these same trusts. 
Similar variations are seen for endoscopy procedures.26   Considerable variations also exist between 
general practices in terms of referrals for suspected cancer, with a threefold difference in referral 
rates between practices in the lowest and highest deciles for referral rate.27  In a study of 8,049 
practices in England and 215,284 patients with cancer, those who were registered with general 
practices with the lowest use of the urgent cancer referral pathway had excess mortality, with a 
hazard ratio of 1.07 (95% confidence interval 1.05 to 1.08), when compared to the intermediate use 
group.28 This difference equates to a clinically significant difference of 5 W6 percentage points in 
cumulative cancer mortality at 4 years between patients registered with low-referring practices, 
compared with high-referring practices.  
 
All of the observational studies described in this section support the hypothesis that increased use of 
cancer diagnostics increases the survival of patients with cancer,29 and they underpinned one of the 
ƐŝǆƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐŽĨŶŐůĂŶĚ ?Ɛ/ŶĚĞƉĞŶĚĞŶƚĂŶĐĞƌdĂƐŬĨŽƌĐĞ W reflective of a national ambition 
to achieve earlier diagnosis.30 This report emphasised the need for both faster, and less restrictive 
investigative testing. The Task Force proposed that, by 2020, 95% of patients referred for further 
testing by a GP should receive a definitive investigation, and the result should be communicated to 
the patient within 4 weeks of the original consultation. However, patients with one of six common 
cancers who were offered initial diagnostic testing in primary care had a median time to referral of 
16 days, compared with a median of zero days for those not offered primary care investigation. This 
data suggests that, if investigations of suspected cancer are to be extensively used by primary care 
physicians, then diagnostic services need to be more responsive than is currently the case.31 
Furthermore, delivery of cancer investigations has important safety, training, and quality 
components, which have to be maintained with any transfer of clinical responsibility for the patient. 
 
[H2] Survival and time to diagnosis 
 
The relationship between time to diagnosis and survival is complex and differs between cancer 
types. Time to diagnosis incorporates three elements: the patient interval, which begins when the 
patient first detects a bodily change; the primary care interval, which begins with first presentation 
to primary care; and the secondary care interval, which begins with referral to a specialist.32, 33 The 
diagnostic interval is the sum of the latter two elements.  
 
A clear relationship between times to diagnosis >3 months and worse survival, relative to those that 
are diagnosed within 3 months of initial presentation (OR 1.47; 95% CI 1.42 W1.53) has been 
demonstrated in a landmark systematic review of 87 studies of patients with breast cancer.34 This 
review did not separate the constituent parts of the time to diagnosis. Studies of the diagnostic 
interval and its association with survival in patients with colorectal cancer have shown a J-curve, 
with the most favourable 3-year survival observed in patients having a diagnostic interval of 28 
days.35, 36 This finding has been replicated using several international datasets.37 After 28 days, the 
slope of the survival curve approximates to a 4% worseŶŝŶŐŽĨƉĂƚŝĞŶƚƐ ? survival outcomes per 
month of additional diagnostic interval.35 Investigators in these studies measured survival from the 
date of diagnosis in order to eliminate lead-time bias (BOX 1). Patients with colorectal cancers 
diagnosed very rapidly have poor survival, either owing to aggressive disease presenting with 
obvious symptoms, thus making diagnosis easier relative to that of patients with less-aggressive 
disease, or because these patients are more likely to present as an emergency.38 Survival also 
decreases as the diagnostic interval increases beyond 28 days owing to the growth of the tumour 
over time.39 Patients with cancers located in other sites might well also have a J-shaped curve for the 
association between time to diagnosis and survival, but the number and methodological strength of 
reports available for any other form of cancer is substantially lower than that available on patients 
with colorectal cancer.39, 40 
 
[H2] Morbidity and time to diagnosis 
 
Reduced morbidity, and particularly improved symptom relief, is an important possible benefit of 
expedited diagnosis; although this aspect has received less attention than survival.41 Diagnostic delay 
is assumed to cause distress, as suggested by data from a small study of 263 patients in Denmark, in 
which a significant association was observed between reported psychological distress and time to 
diagnostic delay (P <0.005), but this result has not been replicated.42 Investigators in another study 
reported no association between patient satisfaction and symptom duration in patients with 
colorectal cancer,43 but elsewhere, data from a different study revealed longer total diagnostic 
intervals to be associated with poorer quality of life than that of patients whose disease was 
diagnosed after a shorter interval, as assessed using the EORTC-C30 scale in patients with 
endometrial (P <0.01) or ovarian cancers (P <0.04).44 Separating the expected distress of receiving a 
diagnosis of cancer from that associated with any additional anxiety caused by diagnostic delay, 
whether perceived or real, is often difficult.42, 45, 46 Initial distress, as measured on an emotional 
distress scale, resulting from the discovery of a symptom of breast cancer is negatively correlated 
with delay in presentation to the health-care system (correlation coefficient -0.29, P =0.01) .47 This 
association might be complicated by the tendency of clinicians to investigate patients with anxiety or 
depression less rapidly than those without such symptoms, as has been demonstrated in patients 
with colorectal cancer.48 In a Delphi technique based study published in 2015, the authors ranked 
the common cancers by how much benefit was to be expected from expedited diagnosis, with breast 
cancer ranked as the most likely, and pancreatic cancer the least.41 Although this study focussed on 
survival benefits, the study also demonstrated that participants believed there to be a morbidity 
benefit of early diagnosis of all types of cancers. Reductions in morbidity from expedited diagnosis 
might also accrue owing to a reduction in the incidence of emergency admissions from cancer.  
[H1] Achieving expedited diagnosis 
[H2] Pre-presentation factors 
For most cancers, the time between first noticing a potential cancer symptom and presenting to the 
health-care system is frequently the greatest proportion of the total time to diagnosis.49 Pre-
presentational times differ between cancers: in a study of 10,297 patients with cancer in England 
conducted between 2009 W2010, patients with oropharyngeal (34%) or oesophageal cancers (39%) 
were most likely to present A?15 days after noticing an initial symptom.50 A study of 2,371 patients, 
with results published in 2014, defined delay as three months or longer and demonstrated that 
patients with prostate (44%) or rectal (37%) cancers are the most likely to delay consultation, 
although this study omitted data from patients with oesophageal cancers.51 Another cohort study of 
963 people in England recruited with symptoms of lung cancer before diagnosis showed that having 
multiple first symptoms is common (only 49.3% of the cohort had a single symptom), that symptoms 
evolve over time, and that people subsequently diagnosed with cancer and those diagnosed with 
non-malignant conditions present with similar symptoms.52  
To expedite diagnosis of symptomatic cancer, understanding how patients recognize possible 
symptoms of cancer and the decisions they make regarding help-seeking is essential. The conceptual 
framework for the pre-presentational interval is now well established,53, 54 and emphasizes the 
influence of patient, health-care system and disease-related factors. However, the precise barriers 
to, and facilitators of entry to health-care systems for each patient with symptoms of cancer are less 
well-understood. SŽŵĞ ‘ĂůĂƌŵ ?symptoms, such as a breast lump, are usually easily recognized as 
possible cancer, while recognition of other symptoms, such as fatigue, is less simple. Symptom 
appraisal can be influenced by: ƚŚĞ ‘ŶŽƌŵĂůŝzĂƚŝŽŶ ?ŽĨĐŽŵŵŽŶƐǇŵƉƚŽŵƐ (where they are perceived 
as an expected part of life, particularly during a liminal phase such as menopause55); the failure to 
interpret the symptom(s) as requiring medical attention; and the difficulties in recognizing new 
symptoms in the presence of other comorbidities.56-58 Symptom appraisal and help-seeking are also 
influenced by psychosocial and cultural contexts, including a fear of stigma, cancer diagnosis and 
treatment, and fatalism, as well as practical barriers to help-seeking, such as a lack of access to 
healthcare and lack of sufficient time and/or transport to attend a consultation.59  
[H2] Symptom awareness campaigns 
Public campaigns aiming to raise awareness of the symptoms of cancer, and to promote help-
seeking, might educate and empower people to hasten earlier presentation.60 Some of these 
campaigns have shown promise, although few report long-term outcomes.60 Public Health England ?Ɛ
 ‘ĞůĞĂƌŽŶĂŶĐĞƌ ?147  campaigns have led to increased public awareness of the headline symptoms 
of lung (recall of 'persistent cough' or 'hoarseness' by 18% versus 26% of patients in 2010 and 2012, 
respectively; P <0.001) and bowel cancer (change in  ‘bowel and/or bladder habits' increased from 
21% to 43%; P <0.01),61 increases in attendances for symptoms by those aged A? ? ?ǇĞĂƌƐ (29% and 
63% increase versus the same weeks in 2011 for the bowel and lung campaigns, respectively,62 and 
more cancers diagnosed (9.1% increase; P <0.001), with a small, but significant, increase in the 
proportion of lung cancers diagnosed at a stage amenable to surgical resection (stage I tumours 
from 14.1% to 17.3% of the cohort; P <0.001 and stage IV tumours from 52.9% to 49% of the cohort; 
P <0.001).63 Considerable resources were expended in evaluating the outcomes of this campaign, 
although, to date, few peer-reviewed publications have resulted from this expenditure. Data from 
tŚĞ ‘/ ?ůůƚĂĐŬůĞŝƚƐŽŽŶ ?h<ƐƚƵĚǇƐŚŽǁĞĚƚŚĂƚĂĐŽŵďŝŶĞĚƉƵďůŝĐĂǁĂƌĞŶĞƐƐĐĂŵƉĂŝŐŶĂŶĚ'W
education programme for lung cancer led to increased chest X-ray referrals by 20%, and lung cancer 
diagnoses by 27%, although most of these additional cancers were of an advanced stage.64 24 
The  ‘HeadSmart: Be Brain Tumour Aware ?148 charity campaign, launched in 2011 across the UK as a 
quality improvement strategy for expediting the diagnosis of brain tumours in children, employed 
guidelines for professionals alongside public awareness campaigns. This campaign has been highly 
effective, with considerable reductions in total diagnostic interval (median 9.1 to 6.7 weeks) and in 
the median interval from first medical contact to CNS imaging (from 3.3 to 1.4 weeks; P <0.009).65, 66 
Whether raising awareness of individual symptoms, or symptom combinations, of other less 
common cancers will also promote more timely help-seeking currently remains unclear.5 Cancer 
ĂǁĂƌĞŶĞƐƐĐĂŵƉĂŝŐŶƐĂůƐŽŶĞĞĚƚŽĂĚĚƌĞƐƐƚŚĞŝƌƚĂƌŐĞƚĂƵĚŝĞŶĐĞ ?ƐŚĞĂůƚŚůŝƚĞƌĂĐǇ ?ǁŝƚŚůŽǁĞƌŚĞĂůƚh 
literacy strongly associated with disadvantaged socio-economic and ethnic minority groups.67  
Linking information on awareness with other healthcare activities ŵŝŐŚƚŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?
awareness: data from a trial that involved offering information about symptoms of breast cancer to 
women attending breast screening revealed an increase in the proportion of women who were 
breast cancer aware from 6%, to 21% (OR 8.1, 95% CI 2.7 W25) when assessed two years later using a 
validated questionnaire.7 
Few studies of interventions promoting earlier presentation to health-care systems, which 
specifically target individuals at an increased risk of cancer, have been conducted. Data from a 
Scottish trial with a cohort of people at a higher risk of lung cancer (smokers and former smokers) 
provides preliminary evidence of altered consulting patterns in this population, in response to an 
intervention comprising a single consultation session with a nurse and provision of a self-help 
manual on lung cancer symptoms;4 interestingly, in order to improve patient engagement, smoking 
cessation was not mentioned. Evidence is now required on the effect of this intervention on clinical 
outcomes as well as consulting behaviour, and on the generalisability of similar interventions to 
other at-risk populations. 
As well as formal awareness campaigns, information on all aspects of cancer is now freely available 
on the internet. Cancer-related searches for information increased during a breast cancer awareness 
campaign.68 Potentially, improvements in diagnosis could be observed in a better-informed 
population, thus improving the survival of those diagnosed with a variety of different cancers. 
[H2] In primary care 
In most countries, symptomatic patients initially present to primary care, although some health-care 
systems allow direct access to specialist care. The clinician must first think of cancer as a possibility, 
and must then decide whether testing is required or not. The first stage of a diagnosis differs greatly 
between cancer types;69 some are relatively simple, such as checking for the presence of a breast 
lump or a pigmented skin lesion. With these symptoms, the doctor, and usually the patient, will 
generally ensure cancer is explicitly addressed in the consultation. Other cancers are notoriously 
difficult to diagnose conclusively, particularly when the symptoms are common features of benign 
conditions. For example, backache is the most frequent symptom of myeloma, although only one in 
a 1,000 adult patients reporting backache will transpire to have myeloma.70 The risk of a brain 
tumour with new-onset headache is similar.71 dŚĞƐĞ ‘ĚŝĨĨŝĐƵlt to diagnose ?ĐĂŶĐĞƌƐĂƌĞcharacterized 
by having three or more primary care attendances before diagnosis; from 10.1% of patients with 
breast cancer, to 50.6% of those with multiple myeloma,72 with high proportions presenting as an 
emergency with a complication of their cancer (including 62% of patients with tumours of the 
CNS),38, 72, 73 and poor outcomes. Counter-intuitively, continuity of primary care (that is, frequently 
consulting with the same clinician in a practice) has only a very small effect upon the rapidity of a 
cancer diagnosis.74  
[H2] Clinical decision support 
Insights into the epidemiology of cancer symptoms in primary care, including estimates of their 
positive predictive value, have enabled the development of risk models, notably Risk Assessment 
Tools and QCancer® (Clinrisk, Nottingham, UK), to predict the likelihood of an undiagnosed cancer in 
symptomatic primary care patients..75-77, 78 , 79 A good level of evidence is available from systematic 
reviews indicating that clinical decision support improves physician performance and the ordering of 
diagnostic tests.80, 81 82 These risk models have been formulated, mostly in the UK, as assessment 
tools for use by GPs.83 The first evaluation of such a risk assessment tool, made available in a printed 
format for the assessment of patients with suspected lung or colorectal cancers, and found that its 
use resulted in an increase in 2-week referrals (by 31% and 26% compared with the 6 months 
immediately preceding the study period for lung and colorectal cancer, respectively) and increased 
use of chest radiography (by 4%) and colonoscopy (by 15%); these changes resulted in a 37% 
increase in the diagnosis of lung cancers, with an increased proportion of stage I or II cancers 
(localized and locally advanced), and a 76% increase in diagnosis of colorectal cancer .84 Risk 
algorithms have been further developed into electronic tools that interact with the ƉĂƚŝĞŶƚ ?Ɛ
individual clinical record. As a joint initiative between Macmillan Cancer Support, Cancer Research 
UK and the NHS, these tools were piloted in over 500 practices in the UK. They enable a doctor to 
enter symptoms and calculate risk, but also prompt the doctor to consider a cancer diagnosis when a 
patient presents features summating to a cancer risk of 2% or more are already recorded. In an 
evaluation funded by the three sponsoring organisations, 19% of urgent referrals for suspected 
cancer from participating GPs were prompted by use of the tool.85 Such tools can, however, conflict 
with clinical judgement, making some GPs reluctant to use them in the consultation, and these tools 
are trusted less by more experienced GPs.86 Furthermore, variation in interpretation of symptoms by 
different clinicians can lead to substantial variations in risk assessment.87 No studies in this area have 
examined the diagnostic utility of clinical judgement when combined with use of evidence-based 
tools, although guidance from the National Institute for Health and Clinical Excellence (NICE), 
published in 2015, explicitly allows clinicians to override the recommendations of decision support 
tools when a good reason to do so exists.88  Evidence for the effect of clinical decision support on 
clinically important outcomes such as stage at diagnosis and survival remains lacking, however, and 
randomized controlled trials such as the Evaluation of a Computer aid for Assessing Stomach 
Symptoms (ECASS) trial are currently ongoing.9 Current risk models are driven by simple algorithms; 
more sophisticated systems, driven by artificial intelligence, are currently in development and will 
likely reach the point of implementation in routine practice in the next few years.83 
In the latest revision of NICE guidance for investigation of suspected cancer, conclusions from the 
papers underpinning the use of clinical decision support tools for the diagnosis of cancer were used 
to formulate the recommendations.88 The tools themselves were not made the subject of a 
recommendation  W either positive or negative  W as these are regarded as a platform for delivery of 
information to clinicians. Seen in this light, the platforms per se had not been sufficiently studied to 
justify a recommendation.  
[H2] Policy-driven initiatives  
The recognition that more expeditious diagnosis of cancer could improve ƉĂƚŝĞŶƚƐ ? outcomes is not 
new.89 However, nearly a century passed, following an address to the British Medical Association in 
1909, before national cancer policies recognized early diagnosis as a key element of cancer care. 
Early government intervention strategies designed to improve the outcomes of patients with cancer 
prioritised advances in treatment, as demonstrated by the 1971 National Cancer Act in the USA. By 
the early 2000s, however, some jurisdictions were seeking to expedite specialist referrals of patients 
with high-risk symptoms, and in the UK a 2-week target was set for the urgency with which patients 
suspected of having cancer should be seen.13, 90 Guidance on selection of patients for urgent referral 
has become a feature of a growing number of health-care systems, notably those in which the GP 
acts as gatekeeper to specialist care.91 Programmes of research aiming to determine the predictive 
value of symptoms have informed this, for example, patients with colorectal cancer often lack a 
single symptom defining high-risk disease, necessitating the introduction of a risk scoring system 75, 76 
thus enabling guidance to be refined, and introducing the possibility of explicit risk thresholds for 
referral.88  
The task of cancer diagnosis could, possibly, be extended beyond general medical practice to other 
providers of primary care. Dental practitioners and opticians identify the majority of oral and uveal 
cancers, respectively.92 The role of pharmacy practitioners is less clear. Patients with, for example, 
cough or epigastric pain, often present to pharmacies and not general practices. Therefore, training 
for pharmacists in cancer diagnosis was included as part of UK awareness campaigns. At present, 
apart from a small number of ongoing pilot studies,93 pharmacists have no access to diagnostic 
testing, so have to refer symptomatic patients elsewhere  W usually to general practice. 
[H1] Patient and population aspects  
Many risk factors for cancer have been identified. Increased age, gender-specific risks, a family 
history of close relatives affected at younger ages, obesity, ethnicity, co-morbidities, smoking and 
excess alcohol intake are among the most important.94 However, the interplay between risk factors 
and symptoms is complex. The risk of cancer in a person with a particular symptom has been 
demonstrated to vary for three of these risk factors  W age, sex, and cigarette smoking.88 For the 
other risk factors, evidence of the association of different likelihoods of cancer with a particular 
symptom  is very weak or absent.88 In the QCancer® series of papers, risk factors and symptoms 
were retained in the same multivariable model; in situations in which a statistically significant 
association was observed between any risk factor and cancer, the odds ratio was generally much 
smaller than those for symptoms. 95-100 In these papers, which used ƉĂƚŝĞŶƚ ?Ɛ pre-existing medical 
records, doctors probably would have recorded the presence of risk factors more frequently in 
patients also presenting with symptoms of possible cancer. This approach generates ascertainment 
bias (BOX 1), which would inflate the apparent strength of associations between the presence of risk 
factors with development of cancer. Arguably, risk factors other than age, sex, and smoking should 
only be used in the selection of patients for screening programmes, and should be omitted from the 
clinical assessment of symptomatic patients.  
Patients from ethnic minorities generally have worse cancer survival than the majority: this 
difference might reflect different biology,101 but patients from ethnic minorities also experience 
more diagnostic delay.102 Furthermore, black patients, compared with white patients, might be less 
willing to opt for clinical investigation of prostate cancer at any risk level, as shown in a vignette 
study of prostate cancer diagnosis.103 
[H2] NICE guidance on patient selection 
Almost all definitive testing for cancer requires biopsy, and thus specialist referral. A small number 
of cancer types can be diagnosed in primary care, such as chronic lymphocytic leukaemia, or 
myeloma.104, 105 Some skin cancers can be identified when excision is performed in primary care  W 
although, if cancer is suspected, specialist excision is generally recommended.88, 106 Point-of-care 
testing has been developed for myeloma, but the performance of this testing has yet to be 
evaluated in the primary care setting. For the remainder of cancer types, the likelihood of cancer at 
the time of referral varies considerably. In some referrals, cancer is highly likely such as when a very 
high lymphocyte count is identified in a blood test, or if an irregular, hard prostate is identified upon 
rectal examination.107 Conversely, some necessary referrals are of the  ‘low-risk, but not no risk ?
patient, such as the patient presenting with persistent diarrhoea or unexplained abdominal pain, 
where the likelihood of cancer is only 1 W2%.108  
Selection of patients for investigation in the UK is largely guided by the NICE, although Scotland has 
its own guidance from the Scottish Intercollegiate Guidelines Network.109 The 2015 version of the 
NICE guidance based its recommendations for investigation on an assessment of the likelihood that 
the patient ?s symptoms (sometimes supplemented by simple primary care tests) exceed a threshold 
risk of cancer of 3%.88 Two broad exceptions to this figure were agreed. For children, the benefits of 
improved survival and/or reduced morbidity are experienced over a longer time, thus making 
investigations of suspected cancer in children at levels 3% risk a reasonable approach. 
Furthermore, very few symptom profiles of cancer in children  W ĞǀĞŶƚŚĞ ‘ŚŝŐŚƌŝƐŬ ?ŽŶĞƐ W represent 
risks !3%,110-112 so using that figure would be extremely restrictive. The second exception was for 
cancers for which primary care testing is widely available, such as serum prostate specific antigen 
testing or chest X-ray. These tests, which are often inexpensive, refine the risk of cancer, such that 
patients with a positive test result have a revised risk of cancer >3%, and test-negative patients <3%. 
Both NICE decisions, to use a risk threshold and the setting of the specific level, are contentious. 
Prior to this recommendation, no threshold had been explicitly used to structure any previous 
cancer guidance  .33 Several possible alternatives to using risk are available as the metric of choice. 
Priority (and by implication, extra resources) could have been given to investigating for cancers that 
are known to result in better patient outcomes from expedited diagnosis. If cost-effectiveness data 
had been available, this could have driven recommendations  W indeed NICE recommendations are 
generally based on estimates of cost-effectiveness. This argument could have been reversed: types 
of cancer with poor survival could justifiably have been given priority in the hope that this would 
improve outcomĞƐ ?ĚĚŝƚŝŽŶĂůůǇ ?ƚŚĞĂǀĂŝůĂďŝůŝƚǇŽĨĚŝĂŐŶŽƐƚŝĐƌĞƐŽƵƌĐĞƐĐŽƵůĚŚĂǀĞŝŶĨůƵĞŶĐĞĚE/ ?Ɛ
recommendations; some diagnostic services, notably those providing imaging and endoscopy, have 
seen considerable expansions in their level of use, and are struggling to meet current levels of 
demand, let alone offer additional ones.113, 114  
The final decision to use positive predictive values (PPVs) for symptomatic cancer derived from 
primary care populations as a threshold has several advantages. This approach brings equity across 
cancers, and could be adjusted if a lower (or higher) figure is later considered to be superior. Being 
numerical, PPVs are also amenable to being integrated into general practice software, thus enabling 
automated calculations of risk based upon symptoms and test results present in medical records, 
and prompting the GP to consider further investigations should this risk be above an agreed 
threshold level.83 Finally, PPVs were available from primary care studies for nearly all of the common 
cancers, and several of the less common ones, as shown by the evidence review within the NICE 
guidance.88 Primary care-derived PPVs differ from those for the referred population, owing to the 
referral selection process creating a population with a substantially higher prevalence of disease.115 
Thus, although the NICE guidance has strong face validity for primary care clinicians,116 some 
specialists expressed concerns that the recommendations failed to match their personal experience 
of the symptomatology of cancer.117  
[H2] Thresholds for cancer investigation  
The final decision by NICE to recommend urgent investigation once ĂƉĂƚŝĞŶƚ ?Ɛ risk of cancer exceeds 
3% is a compromise between a liberalisation of previous guidance and a recognition that many 
members of the public would opt for cancer investigation at much lower levels of risk, even as low as 
1%.118 An additional issue relates to safety: some tests, such as colonoscopy, carry a small risk of 
harm.119 The liberalisation to a 3% threshold for investigation (or lower if simple primary care testing 
is available) theoretically could lead to a major expansion in testing. In practice, much of this has 
already happened: imaging activity increased at 5.7% per annum between 2006 W2015,113 with 
similar increases in use of endoscopy also observed.26 At the same time the number of urgent 
referrals made under ƚŚĞE,^ ‘ƚǁŽ-week wait ? system has risen every year, passing one million in 
2012; this increase has been accompanied by a decrease in the percentage of patients in these 
clinics transpiring to have cancer  ?ƚŚĞ ‘ĐŽŶǀĞƌƐŝŽŶƌĂƚĞ ? ?, but an increase in the proportion of 
patients having their cancer detected by this route.120 The driving force behind this expansion in the 
use of cancer diagnostics is currently not clear: it might reflect an increased awareness of cancer 
among patients, or GPs lowering their individual threshold for investigating, perhaps prompted by 
the major increase in research publications on the topic. At the same time as these attempts to 
expedite cancer diagnosis in the NHS, survival outcomes of patients with cancer in the UK have 
improved, and have narrowed the gap in outcomes relative to those of similar patients in other 
European countries  W for some cancers at least.121  
Internationally, new referral pathways have been developed to support guidelines allowing rapid 
assessment of patients with symptoms of concern. In the UK, Australia, and Canada, for example, 
patients referred using these pathways are seen by a specialist within 14 days. In Denmark, however, 
a patient in a similar situation is seen within four working days and the whole diagnostic pathway 
through to treatment is accelerated.122 These referral pathways reduce the time to diagnosis for 
many, but not all, cancers and have been criticised because their use is restricted to those patients 
with specific, generally high-risk symptoms.123 For example, time to diagnosis in the UK fell more for 
those symptoms that already had the lowest times to diagnosis, and the best patient survival 
outcomes.123, 124 However, giving preference to high-risk presentations excludes around half of all 
symptomatic patients and, consequently, in England only 34% of all cancers in 2013 were diagnosed 
in this way.120  Health services in Scandinavia and the UK have, therefore, developed models of rapid 
assessment for patients with less-specific or lower-risk symptoms.125  
{H2] Influence of diagnostic programmes 
Any programme of investigation of symptoms will, as well as identifying patients with non-malignant 
conditions, identify two separate populations of patients with cancer. The first of these two 
populations is the obvious one, comprising patients in whom the cancer was causing the symptom. 
The second population consists of those patients who happened to have the relevant symptom but 
whose cancer was, in essence, an unrelated finding. Some of these  ‘unrelated ? patients will have co-
morbidities that explain their symptoms; for example, patients with chronic obstructive pulmonary 
disease are at a higher risk of lung cancer because of past smoking, and might well have cough and 
breathlessness, both also symptoms of lung cancer. The size of the  ‘unrelated ? population is 
estimated at 27 W48% of patients with lung cancer, and 12 W32% for those with colorectal cancer.126, 
127 However, the data sources for these figures largely pre-date the increases in testing for cancer in 
the UK,128, 129 and the proportion of unrelated cancers is now probably somewhat smaller.  
[H2] Overdiagnosis  
Overdiagnosis describes the diagnosis of disease in an asymptomatic person that does not result in a 
net benefit for that person.130 Overdiagnosis is much more of a concern for screening programmes, 
but the expansion of diagnostic activity means that overdiagnosis is also possible for patients with 
symptomatic cancer.130 Currently, thyroid cancer, prostate cancer, and melanoma are the most likely 
to be overdiagnosed. In South Korea, for example, the incidence of thyroid cancer rose 15-fold 
between 1993 W2011, with no change in thyroid cancer mortality observed over the same time 
period.131 A similar pattern has been reported in melanoma, with the considerable increase in 
incidence largely representing early stage disease, and also showing no overall change in 
mortality.132 Prostate cancer is a further candidate. In the era where prostatectomy was the 
standard treatment of benign prostatic hyperplasia, incidental prostate cancers  W almost certainly 
unrelated to the ƉĂƚŝĞŶƚ ?Ɛ symptoms  W were frequently identified. Overall, the evidence in this area 
is limited, we suspect that the risks of overdiagnosis from expediting symptomatic diagnosis are 
likely to be relatively small compared to the possible benefits.. 
 
[H1] Health economics  
Health economic analyses of the costs versus benefits of expedited cancer diagnosis in symptomatic 
patients are much less advanced than analyses of the performance of cancer screening. The costs of 
diagnosis have been investigated in several studies, although the benefits much less so.133 Diagnostic 
costs should include the costs of investigation in those whose results transpire to be negative, 
although these costs (which might be substantial) are often omitted.134 Once these costs are 
included, the costs of diagnosis might exceed the costs of primary treatment, as has been estimated 
for patients with symptoms of possible colorectal cancer.135 This finding reflects the high costs of 
colonoscopy relative to approaches used for the diagnosis of other forms of cancer, suggesting that 
costs for patients with other cancers also requiring a form of endoscopy for diagnosis might be 
similar.136 The total annual cost of cancer diagnosis in the UK might be one billion pounds.29  
Comparisons of the costs, per case, of alternative diagnostic strategies are possible. Such a 
comparison was included in the 2015 NICE guidance, whereby several possible testing strategies for 
potential patients with colorectal cancer (whose estimated risk of cancer was <3%) were 
compared.88 Faecal occult blood testing was clearly the most cost-effective approach. However, data 
on the performance characteristics of cancer investigations in primary care populations are rarely 
available, and (debatable) assumptions have to be made that these are similar to reports from 
secondary care or screened populations. Similarly, little is known about adverse events from cancer 
investigation when conducted in primary care.88  
Estimation of the benefits of expedited cancer diagnosis has been much more difficult than 
estimating the cost of implementing such strategies. As described earlier,  evidence from clinical 
trials is insufficient. Establishing the costs of treatment for the various stages of cancer is possible, 
with patients with cancers of a less-advanced stage being cheaper to treat.134 Accurate figures for 
survival, by cancer stage, are also available for most cancers. However, the timescale for transition 
between cancer stages and its relationship with symptomatology is much less well known.137 Gaining 
this knowledge is a crucial step, as until we know what stage shift (if any) arises from the 
introduction of an intervention to expedite symptomatic cancer diagnosis, reliably estimating the 
benefits of such an approach will remain impossible.138 Thus, reports of a small, but significant, stage 
shift following a cancer awareness campaign are doubly welcome.63 These might enable much more 
informative health-economic analyses. 
 
[H1] Conclusions 
The survival of patients with cancer is improving in all developed countries, including the UK, and the 
rate of these improvements shows no sign of slowing down. Some of these improvements are 
almost certainly a result of improved diagnostics. In the UK, times to cancer diagnosis have fallen,123 
and the proportion of patients presenting with cancer as an emergency has also fallen.120 These 
improvements are contemporaneous with major reconfigurations and investment in cancer services 
and with a liberalization of the criteria for cancer investigation, coupled with better identification of 
those who are most at risk. These two themes likely reflect cause and effect  W in part at least. We 
cannot yet know if attempts at early diagnosis have been cost-effective. These initiatives have 
certainly been costly  W but at least we know we are getting something for the money. 
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The provision of rapid access to specialist expertise, coupled with national guidance for selection of 
patients  ?  and, subsequently, clinical decision support  ?  might result in shorter times to diagnosis 
Guidance from the UK National Institute of Health and Care Excellence use an explicit risk threshold 
of 3% for investigation of symptomatic cancer; this liberalisation will influence the spectrum of 
patients seen by specialists 
The cost-effectiveness of initiatives to expedite diagnosis of symptomatic cancer is markedly under-
researched 
  
BOX 1. Common biases seen in observational diagnostic studies 
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testing. PSA and prostate cancer provides another example. If two men with similar urinary 
symptoms both have PSA measured, then the man with a raised PSA is more likely to have definitive 
testing for prostate cancer (in this example, a biopsy) than the man with a normal PSA. This tends to 
inflate sensitivity estimates for the initial test (in this example, the PSA)..22 
Recall bias: this affects studies in which information is collected after the outcome (diagnosis) is 
known. Patients with the outcome of interest, such as cancer, might be more willing to attribute pre-
diagnostic symptoms to their cancer, and be more likely to report them. 
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